These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 20563569)

  • 1. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
    Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
    Gunes A; Spina E; Dahl ML; Scordo MG
    Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10.
    Yoo HD; Lee SN; Kang HA; Cho HY; Lee IK; Lee YB
    Br J Pharmacol; 2011 Sep; 164(2b):433-43. PubMed ID: 21449914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
    Ma L; Xiang Q; Zhao N; Hu C; Fang M; Tan Y; Chen S; Wang Z; Liu P; Sun K; Li Y; Wu F; Tian H; Fang M; Zhao X; Wang G; Cui Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110241. PubMed ID: 33400943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
    Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone plasma levels, clinical response and side-effects.
    Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.
    Yoo HD; Cho HY; Lee SN; Yoon H; Lee YB
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):329-41. PubMed ID: 22623266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes.
    Mas S; Gassò P; Alvarez S; Parellada E; Bernardo M; Lafuente A
    Pharmacogenomics J; 2012 Jun; 12(3):255-9. PubMed ID: 21173786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia.
    Suzuki Y; Tsuneyama N; Fukui N; Sugai T; Watanabe J; Ono S; Saito M; Someya T
    J Clin Psychopharmacol; 2013 Jun; 33(3):411-4. PubMed ID: 23609388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
    Xiang Q; Zhao X; Zhou Y; Duan JL; Cui YM
    J Clin Pharmacol; 2010 Jun; 50(6):659-66. PubMed ID: 20332423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
    Yasui-Furukori N; Mihara K; Takahata T; Suzuki A; Nakagami T; De Vries R; Tateishi T; Kondo T; Kaneko S
    Br J Clin Pharmacol; 2004 May; 57(5):569-75. PubMed ID: 15089809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
    Mihara K; Kondo T; Yasui-Furukori N; Suzuki A; Ishida M; Ono S; Kubota T; Iga T; Takarada Y; de Vries R; Kaneko S
    Ther Drug Monit; 2003 Jun; 25(3):287-93. PubMed ID: 12766554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
    Kakihara S; Yoshimura R; Shinkai K; Matsumoto C; Goto M; Kaji K; Yamada Y; Ueda N; Ohmori O; Nakamura J
    Int Clin Psychopharmacol; 2005 Mar; 20(2):71-8. PubMed ID: 15729081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
    Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
    J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.
    Suzuki Y; Fukui N; Tsuneyama N; Watanabe J; Ono S; Sugai T; Saito M; Inoue Y; Someya T
    Hum Psychopharmacol; 2012 Jan; 27(1):43-6. PubMed ID: 22745940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.
    Cho HY; Lee YB
    Arch Pharm Res; 2006 Jun; 29(6):525-33. PubMed ID: 16833023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
    Kang RH; Jung SM; Kim KA; Lee DK; Cho HK; Jung BJ; Kim YK; Kim SH; Han C; Lee MS; Park JY
    J Clin Psychopharmacol; 2009 Jun; 29(3):272-7. PubMed ID: 19440082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
    Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
    Kneller LA; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.